Efficacy and safety of darunavir-ritonovir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Clotet C, Bellos N, Molina J et al. Lancet, 2007, 369, 1169-1178. Review by Derek J Chan Division of Sexual Health, Prince of Wales Hospital, Sydney, Australia
The randomised multinational, phase IIb studies POWER 1 and 2 compared the virological efficacy of several dosages of darunavir-ritonovir (DRV/RTV) plus optimised background therapy (OBT) with control protease inhibitors (PIs) plus OBT. By week 48, 58% of patients in POWER 1 and 39% in POWER 2 taking DRV/RTV 600/100mg twice daily attained viral load
The overall discontinuation rate was higher in the control PI arm compared to the DRV/RTV arm and was mainly attributable to virological failure. None the less, the rate of discontinuation did not affect the efficacy analyses of either arm: the difference between treatments was already well established by week 12 and 100 subjects (76%) in the DRV/RTV arm and 29 (23%) in the control PI arm attained a viral load decrease of at least 1 [log.sub.10]...